SUBSCRIBE Blog with us: BLOGbiotech

Breaking News

• Email
• Print
• Share
• More News

Jun 6 2007, 1:05 PM EST

Barrier Therapeutics Introduces New 50g-Size Tube of Vusion(R) Ointment

MARKETWIRE

Jun 06, 2007 PRINCETON, NJ MARKET WIRE

Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company that develops and markets dermatology products, today announced that it has launched a new 50g-size tube of its Vusion(R) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment. Vusion Ointment is the only prescription product approved in the U.S. for the treatment of diaper dermatitis, also known as diaper rash, complicated with a documented fungal infection caused by yeast known as Candida.

"We are pleased to offer this larger 50g tube size in response to physician requests and as part of our strategic plan announced last month to optimize the value of this brand," said Al Altomari, Chief Operating Officer of Barrier Therapeutics.

In March 2007, the company entered into an agreement with Novartis Consumer Health, Inc. whereby Novartis Consumer Health is promoting Vusion Ointment to pediatricians in the U.S. Novartis Consumer Health began promoting Vusion Ointment in May 2007, supplementing the efforts of Barrier Therapeutics' 60-person sales force.

About Vusion Ointment and Diaper Dermatitis Complicated by Documented Candidiasis (DDCC)

Vusion Ointment is specifically formulated for the treatment of DDCC in immunocompetent infants and children four weeks and older. Vusion is a steroid-free formulation that contains the active ingredient miconazole nitrate at a concentration of 0.25%, which directly treats the infection with proven antifungal efficacy. The ointment base for Vusion is comprised of zinc oxide and white petrolatum, which are the main components in most common diaper rash products. In clinical trials, Vusion showed statistically significant improvement within three days of treatment in infants with DDCC.

DDCC occurs when diaper dermatitis is complicated with a fungal infection caused by yeast known as Candida. The existence of Candida is readily determined by microscopic evaluation for presence of pseudohyphae or budding yeast. There are approximately eight million infants under the age of two in the U.S., and it is estimated that diaper dermatitis is observed in approximately one million pediatric outpatient visits each year. Of the diaper dermatitis cases treated by physicians, it is estimated that more than 40 percent are complicated by the yeast Candida. Until the FDA approved Vusion Ointment, common treatment options included the use of antifungal products, steroids, and combination products not specifically approved for the treatment of DDCC or for use on infants.

For more information on Vusion Ointment, please call 1-866-440-5508 or visit the product website at www.vusionointment.com. For full prescribing information, please visit www.vusionointment.com.

About Barrier Therapeutics

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel(TM) (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion(R) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and acute fungal infections. The company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Can

• Email
• Print
• Share
• More News

CAREER CENTER

WEBINARS

PODCASTS

MOST POPULAR